Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

News Daily News

FDA Approves Finerenone for HF Patients With Mildly Reduced or Preserved EF

Caitlin E. Cox

July 14, 2025

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

News Daily News

FINEARTS-HF: Topline Results Support Role for Finerenone in Mildly Reduced or Preserved EF

L.A. McKeown

August 05, 2024

News Conference News ESC 2023

ESC Focused Update on HF Synthesizes New Trial Data for Practical Use

L.A. McKeown

September 01, 2023

News Daily News

AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD

Caitlin E. Cox

December 28, 2021

News Conference News ESC 2021

Finerenone Reduces CV Outcomes in Patients With Early CKD, Diabetes: FIGARO-DKD

Michael O'Riordan

August 28, 2021

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for July 2021

Shelley Wood

August 02, 2021

News Daily News

FDA Approves Finerenone for Adults With CKD and Type 2 Diabetes

Yael L. Maxwell

July 09, 2021

News Daily News

Finerenone Cuts CV Events in CKD Patients With Diabetes: FIGARO-DKD

Michael O'Riordan

May 11, 2021

News Conference News AHA 2020

FIDELIO-DKD: Finerenone Cuts CV Events in Diabetic Kidney Disease

Todd Neale

November 16, 2020

News Industry News

Bayer Expands Finerenone Clinical Development Program with Three Phase III Studies for Finerenone in Patients with Diabetic Kidney Disease and Patients with Chronic Heart Failure

August 31, 2015

Advertisement

FDA Approves Finerenone for HF Patients With Mildly Reduced or Preserved EF

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

FINEARTS-HF: Topline Results Support Role for Finerenone in Mildly Reduced or Preserved EF

ESC Focused Update on HF Synthesizes New Trial Data for Practical Use

AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD

Finerenone Reduces CV Outcomes in Patients With Early CKD, Diabetes: FIGARO-DKD

TCTMD’s Top 10 Most Popular Stories for July 2021

FDA Approves Finerenone for Adults With CKD and Type 2 Diabetes

Finerenone Cuts CV Events in CKD Patients With Diabetes: FIGARO-DKD

FIDELIO-DKD: Finerenone Cuts CV Events in Diabetic Kidney Disease

Bayer Expands Finerenone Clinical Development Program with Three Phase III Studies for Finerenone in Patients with Diabetic Kidney Disease and Patients with Chronic Heart Failure

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content